General Surgery Devices are used in diagnostic and surgical interventions primarily for the gastrointestinal tract, abdomen, and pelvis. Embolization is an intervention that uses particles such as tiny gelatin sponges or beads to block a blood vessel. GlobalData uses proprietary data and analytics to provide a comprehensive report on the embolization particles devices market, including market shares of different players within China. Buy the latest report here.
Smarter leaders trust GlobalData
In 2023, GlobalData’s Market Model methodology determined that the leading player in the embolization particles market in China was Boston Scientific followed by Varian Medical Systems, Terumo, Merit Medical Systems and Cook Medical.
Embolization Particles are used to stop bleeding or to block the flow of blood to a tumor. These particles are generally used to treat liver cancer, renal cell carcinoma, kidney cancer, neuroendocrine tumors, arteriovenous malformation, uterine fibroids and benign prostatic hyperplasia. Despite having similar appearances and handling characteristics, each one of the embolic agents have specific physical and chemical properties that affects their in vivo behavior. Clinicians have to familiarize themselves with these differences to make the correct choice of embolic agent, and then use the correct protocol for embolization. The sizes of embolization particles can range from 30 to 1200 µm, depending on the indication. Embolization Particles include Drug-Eluting Beads, Microspheres, PolyVinyl Alcohol (PVA) Particles, and Radioembolization Particles.
The value of the embolization particles devices market within China was expected to be over $20m in 2023.
For the latest complete market share analysis of embolization particles device market in China, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. Pipeline Products database is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.
